Use of the Probasin Promoter ARR2PB to Express Bax in Androgen Receptor-Positive Prostate Cancer Cells
Francesca Andriani(Centro Cardiologico Monzino), Marco Marcelli(Baylor College of Medicine), Siegfried Kasper(Medical University of Vienna), Shunsuke Kagawa(Okayama University Hospital), Jingxing Yu(Baylor College of Medicine), Nancy L. Weigel(Baylor College of Medicine), Michael J. McPhaul(Southwestern Medical Center), Robert J. Matusik(Vanderbilt University Medical Center), Bin Nan(Baylor College of Medicine), M Kellis(University of Science and Technology of China), Larry Denner(General Department of Preventive Medicine), Bingliang Fang(The University of Texas MD Anderson Cancer Center)
Cited by 36
Related Papers
Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
|World Psychiatry|2023|751
Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers
|Nature Genetics|2015|744
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
|American Journal of Psychiatry|2021|707